cancer

By mapping the evolution of cancer cells in patients with myelodysplastic syndromes who later died of leukemia, Timothy Graubert, Matthew Walter and their Washington University colleagues have found clues to suggest that targeted cancer drugs should be aimed at mutations that develop early in the disease.

Researchers, including Richard Wilson, PhD, director of The Genome Institute, have identified the first gene mutation associated with a chronic and often fatal form of neuroblastoma that typically strikes adolescents and young adults. The finding provides the first clue about the genetic basis of the long-recognized but poorly understood link between treatment outcome and age at diagnosis.

Life-threatening bacterial infections and brain tumors are just some of the serious health issues affecting children. Now, 12 Washington University School of Medicine research teams are preparing to ask – and answer – critical questions about these and other pediatric health problems with help from $3 million in new grants from the Children’s Discovery Institute, led by Mary Dinauer, MD, PhD.

p, , {margin:0in;margin-bottom:.0001pt;font-size:12.0pt;font-family:Cambria;} .t {font-size:10.0pt;font-family:Cambria;} @page WordSection1 {size:8.5in 11.0in;margin:1.0in 1.25in 1.0in 1.25in;} div.WordSection1 {page:WordSection1;} Scientists at Washington University School of Medicine are using a new imaging device that simultaneously performs positron-emission tomography (PET) and magnetic resonance imaging (MRI) scans, producing more detailed images than either technique alone. The scanner’s power and versatility will enable many wonderful applications in areas ranging from cancer to neurological disorders to heart and lung disease.

DNA sequences from tumor cells can be used to direct the immune system to attack cancer, according to Robert Schreiber, PhD, the Alumni Professor of Pathology and Immunology at Washington University School of Medicine in St. Louis. The research, in mice, appears online Feb. 8 in Nature.

New research from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) shows that mutations linked to a rare, lethal childhood tumor of the brainstem play a unique role in other aggressive pediatric brain tumors. The findings offer important insight into a poorly understood tumor that kills more than 90 percent of patients within two years.

Washington University School of Medicine and Barnes-Jewish Hospital have broken ground on the new Alvin J. Siteman Cancer Center in south St. Louis County. Located on the southeast corner of the intersection of Interstate 55 and Butler Hill Road, the new facility will provide comprehensive outpatient cancer care that is more convenient for patients living in south St. Louis County and the surrounding area.

Washington University in St. Louis has licensed to Castle Biosciences Inc. the exclusive use of a gene to detect the spread of cancer in melanoma patients. A link between the BAP1 gene and cancer metastasis was discovered by Washington University scientists J. William Harbour, MD, an ophthalmologic oncologist, and Anne Bowcock, PhD, a geneticist.

Workers unwrap the world’s first superconducting synchrocyclotron proton accelerator at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis. The device is part of a proton therapy system being installed at Washington University Medical Center at the Kling Center for Proton Therapy,

A newly established fund to support innovative cancer research at the Alvin J. Siteman Cancer Center has awarded its first two $900,000 grants to high-tech efforts to undermine cancer cells’ ability to resist treatment. The awards will help scientists use genetic data to find new ways to attack treatment-resistant breast cancer and precisely target treatments for various kinds of cancer cells based on their responses to radiation therapy.